PersonFounderScientist
Clayton Rabideau
Clayton Rabideau is the founder and CEO of Syntensor, a San Francisco startup building foundation models and mechanistic simulations of human cell biology to predict drug efficacy, toxicity, and the hidden causes of clinical-trial failure. A Cambridge PhD in chemical engineering and biotechnology, he works at the seam between dynamical-systems mathematics and genomics - a co-author on HyenaDNA, the NeurIPS 2023 spotlight that stretched genomic language models to a million bases of context. He is trying to make biology as fast, iterative, and programmable as software.
syntensorfounderceobiotechnologydrug discoveryai for biology